-
公开(公告)号：PT929578E
公开(公告)日：2003-09-30
申请号：PT97906572
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： WHITE MICHAEL , WILTON ALISON JANE , SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J
IPC: C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68 , C12N15/13 , C12N15/64
Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
-
公开(公告)号：NO20026239L
公开(公告)日：2003-02-27
申请号：NO20026239
申请日：2002-12-27
Applicant: ABBOTT LAB
Inventor： COLLINSON ALBERT , GHAYUR TARIQ , AVGERINOS GEORGE , DIXON RICHARD WOODWARD , KAYMAKCALAN ZEHRA
IPC: G01N33/50 , A61K39/395 , A61K47/48 , A61K49/00 , A61P1/04 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/06 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/15 , G01N33/53 , G01N33/68
Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.
-
公开(公告)号：AU2007202323B9
公开(公告)日：2012-02-02
申请号：AU2007202323
申请日：2007-05-23
Applicant: ABBOTT LAB
Inventor： DIXON RICHARD , GHAYUR TARIQ , COLLINSON ALBERT , KAYMAKCALAN ZEHRA , AVGERINOS GEORGE
IPC: G01N33/50 , A61K39/395 , A61K47/48 , A61K49/00 , A61P1/04 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/06 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/15 , G01N33/53 , G01N33/68
Abstract: DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING Abstract Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, 5 recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-la and IL-1# and neutralize IL-la and IL-l# activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for 1o detecting two different but structurally related antigens (e.g., IL-la and IL-1#) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-la and/or IL-13 activity is detrimental.
-
公开(公告)号：ES2319866T3
公开(公告)日：2009-05-14
申请号：ES01950668
申请日：2001-06-28
Applicant: ABBOTT LAB
Inventor： COLLINSON ALBERT , GHAYUR TARIQ , AVGERINOS GEORGE , DIXON RICHARD , KAYMAKCALAN ZEHRA
IPC: C12N15/13 , G01N33/50 , A61K39/395 , A61K47/48 , A61K49/00 , A61K51/10 , A61P1/04 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/06 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/63 , C12P21/08 , G01N33/15 , G01N33/53 , G01N33/577 , G01N33/68
Abstract: Un método para obtener un anticuerpo de especificidad dual o parte de unión al antígeno del mismo, que se une específicamente a dos proteínas diferentes pero relacionadas estructuralmente, comprendiendo el método: proporcionar un antígeno diseñado sobre la base del corte y empalme de partes solapantes entre sí de las dos proteínas diferentes pero relacionadas estructuralmente para crear un péptido híbrido, donde dicho péptido híbrido tiene una estructura X-Y-Z, en la que Y representa una región de identidad o de fuerte similitud entre las dos proteínas relacionadas, X representa una región de una de las proteínas relacionadas y Z representa una región de la otra de las proteínas relacionadas; exponer un repertorio de anticuerpos al antígeno; y seleccionar del repertorio un anticuerpo que se una específicamente a las dos proteínas diferentes pero relacionadas estructuralmente para obtener de esta manera el anticuerpo de especificidad dual.
-
公开(公告)号：AU2007202323A1
公开(公告)日：2007-06-14
申请号：AU2007202323
申请日：2007-05-23
Applicant: ABBOTT LAB
Inventor： DIXON RICHARD , GHAYUR TARIQ , COLLINSON ALBERT , KAYMAKCALAN ZEHRA , AVGERINOS GEORGE
-
Patent Agency Ranking
公开(公告)号：ZA200210109B
公开(公告)日：2004-03-12
申请号：ZA200210109
申请日：2002-12-12
Applicant: ABBOTT LAB
Inventor： COLLINSON ALBERT , AVGERINOS GEORGE , KAYMAKCALAN ZEHRA , GHAYUR TARIQ , DIXON RICHARD
IPC: G01N33/50 , A61K39/395 , A61K47/48 , A61K49/00 , A61P1/04 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/06 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/15 , G01N33/53 , G01N33/68 , C12N , C07K , G01N , A61K , A61P , A01K
Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.
-
公开(公告)号：CZ2003291A3
公开(公告)日：2003-05-14
申请号：CZ2003291
申请日：2001-06-28
Applicant: ABBOTT LAB
Inventor： COLLINSON ALBERT , GHAYUR TARIQ , AVGERINOS GEORGE , DIXON RICHARD , KAYMAKCALAN ZEHRA
IPC: G01N33/50 , A61K39/395 , A61K47/48 , A61K49/00 , A61P1/04 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/06 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/15 , G01N33/53 , G01N33/68 , G01N33/577 , A61K51/10 , C12N15/63
Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.
-
公开(公告)号：AU7163601A
公开(公告)日：2002-01-14
申请号：AU7163601
申请日：2001-06-28
Applicant: ABBOTT LAB
Inventor： COLLINSON ALBERT , GHAYUR TARIQ , AVGERINOS GEORGE , DIXON RICHARD , KAYMAKCALAN ZEHRA
IPC: G01N33/50 , A61K39/395 , A61K47/48 , A61K49/00 , A61P1/04 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/06 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/15 , G01N33/53 , G01N33/68 , G01N33/577 , A61K51/10 , C12N15/63 , C07K14/545 , A01K67/027
Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.
-
19.发明专利
公开(公告)号：PL208069B1
公开(公告)日：2011-03-31
申请号：PL35999501
申请日：2001-06-28
Applicant: ABBOTT LAB
Inventor： COLLINSON ALBERT , GHAYUR TARIQ , AVGERINOS GEORGE , DIXON RICHARD , KAYMAKCALAN ZEHRA
-
公开(公告)号：RO123028B1
公开(公告)日：2010-07-30
申请号：RO200500050
申请日：1997-02-10
Applicant: ABBOTT LAB BERMUDA LTD
Inventor： SALFELD JOCHEN G , ALLEN DEBORAH J , KAYMAKCALAN ZEHRA , LABKOVSKY BORIS , MANKOVICH JOHN A , MCGUINNESS BRIAN T , ROBERTS ANDREW J , SAKORAFAS PAUL , HOOGENBOOM HENDRICUS R J M , SCHOENHAUT DAVID , VAUGHAN TRISTAN J , WHITE MICHAEL , WILTON ALISON J
IPC: C07K14/525 , C12N15/09 , A61K31/00 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/529 , A61K31/57 , A61K31/573 , A61K31/675 , A61K38/00 , A61K38/04 , A61K38/16 , A61K39/39 , A61K39/395 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/10 , A61P7/00 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/16 , A61P13/12 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/06 , A61P25/00 , A61P27/02 , A61P29/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P39/02 , C07K16/24 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/564 , G01N33/576 , G01N33/68
Abstract: Invenţia se referă la un anticorp recombinant uman, care se leagă la factorul de necroză umană alpha (hTNF alpha ) care are afinitate pentru hTNFalpha, Kd = 10-8M sau mai mică, şi o constantă a vitezei Koff de 1 x 10-3s-1 sau mai mică, şi neutralizează activitatea in vitro şi in vivo, precum şi la un acid nucleic care îl codifică, celula gazdă care cuprinde un vector de expresie recombinant, precum şi la o compoziţie farmaceutică ce cuprinde anticorpul, administrată în tratamentul bolilor în care activitatea TNFalfa este dăunătoare.
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.024 seconds)
